Biospecifics Technologies Corp.: Exhibit 24 - prepared by newsfilecorp.com

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AN1u65SKU+7RT/eLis4xSgE2/N4gJWqkfdmXD+jO4xnceAXbBIdhZm3Xt6+mbLAR +z6mr0tyeyVmE8ZEn5ll4A== 0001062993-10-001444.txt : 20100505 0001062993-10-001444.hdr.sgml : 20100505 20100505113623 ACCESSION NUMBER: 0001062993-10-001444 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090911 FILED AS OF DATE: 20100505 DATE AS OF CHANGE: 20100505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gitman Paul CENTRAL INDEX KEY: 0001375378 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 10800248 MAIL ADDRESS: STREET 1: 167 EXECUTIVE DRIVE CITY: MANHASSET HILLS STATE: NY ZIP: 11040 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 4/A 1 form4a.xml AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0303 4/A 2009-09-11 2009-09-15 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001375378 Gitman Paul 167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040 1 0 0 0 Common Stock 2009-09-11 4 M 0 4000 2.563 A 52500 D Common Stock 2009-09-11 4 S 0 4000 25.304 D 48500 D Common Stock 2009-09-14 4 M 0 1000 2.563 A 49500 D Common Stock 2009-09-14 4 S 0 1000 26.999 D 48500 D Common Stock 2009-09-14 4 M 0 5000 2.563 A 53500 D Common Stock 2009-09-14 4 S 0 5000 27.654 D 48500 D Common Stock 2009-09-15 4 M 0 5000 1.00 A 53500 D Common Stock 2009-09-15 4 S 0 5000 27.469 D 48500 D Common Stock 2009-09-14 4 M 0 5000 1.00 A 53500 D Common Stock 2009-09-14 4 S 0 5000 26.999 D 48500 D Common Stock 2009-09-11 4 S 0 2020 25.40 D 5480 I Held by spouse Common Stock 2009-09-14 4 S 0 5480 26.718 D 0 I Held by spouse Stock Option (Right to Buy) 2.563 2009-09-11 4 M 0 4000 0 D 2005-06-05 2010-06-04 Common Stock, $.001 par value 4000 180425 D Stock Option (Right to Buy) 2.563 2009-09-14 4 M 0 6000 0 D 2005-06-05 2010-06-04 Common Stock, $.001 par value 6000 174425 D Stock Option (Right to Buy) 1 2009-09-14 4 M 0 5000 0 D 2002-04-19 2011-04-18 Common Stock, $.001 par value 5000 169425 D Stock Option (Right to Buy) 1 2009-09-15 4 M 0 5000 0 D 2002-04-19 2011-04-18 Common Stock, $.001 par value 5000 164425 D This item has been revised to reflect the correct price by changing $25.3 to $25.304. These items have been revised to reflect the correct number of shares that were acquired with an exercise price of $2.563 per share and then disposed of at a price of $26.999 per share by changing 6,000 to 1,000. The previous filing had incorrectly reported an additional 5,000 shares as having been acquired and disposed of at such prices. These 5,000 shares have been reported in this amendment in two additional items as described in footnote 7 below. This item has been revised to reflect the correct amount by changing 54,500 to 49,500. This item has been revised to reflect the correct exercise price by changing $1 to $2.563. This item has been revised to reflect the correct price by changing $27.65 to $27.654. This item has been revised to reflect the correct price by changing $28.28 to $27.469. These items have been added to reflect the correct exercise and sales prices for the 5,000 shares described in footnote 2 above. These shares were acquired with an exercise price of $1.00 per share and then disposed of at a price of $26.999 per share. This amendment to the Form 4 previously filed on September 15, 2009 is being filed solely to correct certain prices set forth in Table 1 as described above. Exhibit 24 - Power of Attorney /s/ Paul Gitman by Carl A. Valenstein, attorney in fact 2010-05-05 EX-24 2 exhibit24.htm POWER OF ATTORNEY Biospecifics Technologies Corp.: Exhibit 24 - prepared by newsfilecorp.com

POWER OF ATTORNEY

(Section 16 Filings)

Know all by these presents, that the undersigned hereby constitutes and appoints Carl A. Valenstein, Kevin A. Hughes and Kelly E. W. Grez, each individually, as the undersigned’s true and lawful attorneys-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as a director of BioSpecifics Technologies Corp. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that neither of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 23rd day of January, 2010.

/s/ Paul Gitman
Name: Paul Gitman

-----END PRIVACY-ENHANCED MESSAGE-----